Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page now presents the LIBRETTO-431 study of selpercatinib for advanced or metastatic RET fusion-positive non-small cell lung cancer, with detailed study design, participation criteria, locations, and published results.
    Difference
    100%
    Check dated 2026-11-10T19:59:36.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T20:09:33.000Z thumbnail image
  3. Check
    25 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision label advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T20:35:21.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T20:49:23.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    The LIBRETTO-431 page now shows a 403 Forbidden error, replacing the previous study details and removing associated documents, effectively blocking access to the trial's information.
    Difference
    19%
    Check dated 2026-09-22T22:18:54.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page underwent a revision bump from v3.6.6 to v3.7.0, indicating a platform/template upgrade for the ClinicalTrials.gov page. This update does not modify the study details or displayed data.
    Difference
    0.0%
    Check dated 2026-09-15T20:46:31.000Z thumbnail image

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.